Immuno-Oncology Veteran Rachel Humphrey Joins CytomX
This article was originally published in Scrip
CytomX Therapeutics, Inc., a biopharmaceutical company developing therapeutics for the treatment of cancer, has appointed Dr. Rachel Humphrey chief medical officer. Humphrey formerly led immuno-oncology at Eli Lilly and AstraZeneca; oversaw clinical development of Yervoy (ipilmumab), the first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb; and played a role in the development of Nexavar (sorafenib) at Bayer. She was also previously a member of CytomX's board of directors.
You may also be interested in...
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.